Reapplix A/S
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Reapplix A/S - overview
Established
2008
Location
-, -, Denmark
Primary Industry
Healthcare
About
Reapplix Inc. specializes in innovative wound healing solutions, particularly addressing diabetic foot ulcers with its 3C Patch® System, which utilizes patient-derived blood components to facilitate healing. Reapplix Inc. , founded in 2008 in Denmark, develops advanced treatments for chronic wounds.
The company has not undergone any significant strategic pivots and operates independently. Rasmus Lundquist is the founder, while Kira Rupprecht serves as the CEO. Reapplix has raised a total of DKK 150. 000 mn across multiple funding rounds, with the most recent round in November 2021, attracting investors such as Lauxera Capital Partners, MK Ventures, North-East Venture, Novo Holdings, and Vaekstfonden.
Reapplix focuses on innovative wound healing solutions, particularly for diabetic foot ulcers. Its flagship 3C Patch® System utilizes a small sample of the patient's blood to create a patch rich in proteins and growth factors that is applied at the wound site. The product aims to accelerate healing, addressing the issue that roughly 60% of diabetic foot ulcers do not heal with traditional treatments. Reapplix's technology is clinically validated and is recommended by the International Working Group on the Diabetic Foot (IWGDF).
The company's products are marketed to healthcare professionals across international markets, including Europe and the United States. Reapplix plans to expand its product offerings and is currently working on upcoming innovations within the wound care sector. The company aims to enter new geographic markets, specifically targeting expansion into additional regions in Europe and the United States by 2023. The funding raised in November 2021 will be utilized to support these initiatives, enhancing product development and market penetration.
Current Investors
SEED Capital, Vaekstfonden, Novo Holdings
Primary Industry
Healthcare
Sub Industries
Healthcare, Therapeutic Devices
Website
www.reapplix.com
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Reapplix A/S - timeline of key events
Reapplix A/S - financials
| Fiscal Year Ended | Apr 30, 2010 | Apr 30, 2011 | Apr 30, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | 48,950 | 116,290 | 71,000 | 191,000 | 656,000 | 733,000 | 1,611,000 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | 137.6% | (38.9%) | 169.0% | 243.5% | 11.7% | 119.8% | - | - | - |
| EBITDA (USD) | (1,726,005) | (3,508,048) | (4,998,778) | (4,813,590) | (11,600,058) | (17,144,921) | (18,044,396) | (18,787,044) | (29,627,000) | (43,362,000) | (34,356,000) | (35,514,000) | - | - | - |
| Operating Income (USD) | (1,752,784) | (3,542,572) | (5,061,275) | (4,843,259) | (11,636,780) | (17,179,443) | (18,049,756) | (18,787,044) | (30,205,000) | (44,588,000) | (36,559,000) | (37,845,000) | - | - | - |
| Operating Margin | - | - | - | - | - | (35095.9%) | (15521.3%) | (26460.6%) | (15814.1%) | (6797.0%) | (4987.6%) | (2349.2%) | - | - | - |
| % EBITDA Margin | - | - | - | - | - | (35025.4%) | (15516.7%) | (26460.6%) | (15511.5%) | (6610.1%) | (4687.0%) | (2204.5%) | - | - | - |
| NET Income (USD) | (1,763,200) | (3,565,147) | (5,156,718) | (3,608,010) | (8,759,407) | (13,717,128) | (14,988,889) | (17,234,663) | (37,953,000) | (89,617,000) | (35,384,000) | (31,416,000) | - | - | - |
| % Net Margin | - | - | - | - | - | (28022.7%) | (12889.2%) | (24274.2%) | (19870.7%) | (13661.1%) | (4827.3%) | (1950.1%) | - | - | - |
Reapplix A/S - employee data
Reapplix A/S - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Chairman Of The Board | BM | ||||||
| Chairman of the board/board member from Oct. 1 2015 | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.